537 related articles for article (PubMed ID: 18638614)
1. Management of hypertension in patients with chronic kidney disease and diabetes mellitus.
Palmer BF
Am J Med; 2008 Aug; 121(8 Suppl):S16-22. PubMed ID: 18638614
[TBL] [Abstract][Full Text] [Related]
2. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Julius S
Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.
Abuissa H; Jones PG; Marso SP; O'Keefe JH
J Am Coll Cardiol; 2005 Sep; 46(5):821-6. PubMed ID: 16139131
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
5. Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease.
Ferrari P
Nephrology (Carlton); 2007 Feb; 12(1):81-9. PubMed ID: 17295666
[TBL] [Abstract][Full Text] [Related]
6. Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects.
Katragadda S; Arora RR
Am J Ther; 2010; 17(1):e11-23. PubMed ID: 20090429
[TBL] [Abstract][Full Text] [Related]
7. Renal protection with angiotensin receptor blockers: where do we stand.
Schmieder RE; Ruilope LM; Barnett AH
J Nephrol; 2011; 24(5):569-80. PubMed ID: 21404225
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for the development and progression of renal diseases in disadvantaged populations: role of the renin-angiotensin system blockade.
Maione A; Strippoli GF
Ethn Dis; 2009; 19(1 Suppl 1):S1-86-9. PubMed ID: 19484883
[TBL] [Abstract][Full Text] [Related]
9. Improving microvascular outcomes in patients with diabetes through management of hypertension.
McGill JB
Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
Epstein BJ; Gums JG
Ann Pharmacother; 2005 Mar; 39(3):470-80. PubMed ID: 15701766
[TBL] [Abstract][Full Text] [Related]
11. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
Abassi Z; Armaly Z; Nakhoul F; Hoffman A
Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
[TBL] [Abstract][Full Text] [Related]
12. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
Toto R; Palmer BF
Am J Nephrol; 2008; 28(3):372-80. PubMed ID: 18073461
[TBL] [Abstract][Full Text] [Related]
13. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Weber MA
Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
[TBL] [Abstract][Full Text] [Related]
14. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.
Karalliedde J; Viberti G
J Hum Hypertens; 2006 Apr; 20(4):239-53. PubMed ID: 16452996
[TBL] [Abstract][Full Text] [Related]
15. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
[TBL] [Abstract][Full Text] [Related]
16. Microalbuminuria as a target to improve cardiovascular and renal outcomes.
Basi S; Lewis JB
Am J Kidney Dis; 2006 Jun; 47(6):927-46. PubMed ID: 16731288
[TBL] [Abstract][Full Text] [Related]
17. Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus.
Reboldi G; Gentile G; Angeli F; Verdecchia P
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1349-61. PubMed ID: 19900018
[TBL] [Abstract][Full Text] [Related]
18. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy.
Giles TD
Rev Cardiovasc Med; 2007; 8 Suppl 2():S14-21. PubMed ID: 17401312
[TBL] [Abstract][Full Text] [Related]
19. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension.
Tocci G; Sciarretta S; Facciolo C; Volpe M
Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):767-76. PubMed ID: 17605654
[TBL] [Abstract][Full Text] [Related]
20. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]